A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis | Bentham Science
Login Register Cart 0
Generic placeholder image

Recent Patents on Drug Delivery & Formulation

Editor-in-Chief

ISSN (Print): 1872-2113
ISSN (Online): 2212-4039

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis

Author(s): Ankita Gupta*, Swatantra Singh Kushwaha and Amit Mishra

Volume 14, Issue 2, 2020

Page: [126 - 144] Pages: 19

DOI: 10.2174/1872211314666200914155051

Price: $65

Open Access Journals Promotions 2
Abstract

Background: Cancer is a condition in which some cells in the body grow uncontrollably and can also spread in other parts of the body. Among males, oral and lung cancers account for 25 % cancer deaths, while in females, breast and oral cancers cause 25% death. Breast and cervical cancers are the underlying cause of the high mortality rate among women. Owing to limitations of conventional cancer therapy like low drug specificity, less solubility, multidrug resistance, poor access to tumor cells and low bioavailability development of environmentally sensitive and target specific nanocarriers are imperative.

Objective: The objective of this study is to review advancements made in techniques to synthesize Mesoporous Silica Nanoparticles (MSN’s) as well as strategies to functionalize its silanol group for site-specific drug release in the tumor environment and to review recent patents published regarding it. To describe rationale for selection of MSN’s for cancer theranostics amidst other nanocarriers developed.

Methods: In the first section of this review, the physical and chemical properties of MSNs making it an ideal delivery system for cancer therapy and diagnostics are discussed. In the next section, various techniques involved in synthesizing and loading MSNs, including the influence of basic components of MSNs and reaction conditions on its properties are reviewed. Then the wide application of MSNs and various exogenous and endogenous stimuli harnessed for site-specific delivery of cargo and recent patents on modifying environmental conditions for large scale synthesis of MSNs and its active targeting for cancer treatment and bioimaging are discussed.

Results: Physico-chemical properties and synthetic protocols of MSNs justifying them to be a promising nanovector to overcome the ill effects of traditional chemotherapy. The superlative attributes of MSNs including, tunable size, morphology, high load volume, stability, ease of modifying external and internal surface leverage applications in various dimensions of therapeutics, diagnostics, and combinatorial drug delivery. MSNs surface functionalization can be harnessed for passive and active targeting by either coating the surface with polymers or attaching various ligands.

Conclusion: An ideal nano-carrier must have high loading efficiency, easily detectable, and must have stimuli's sensitive, site-specific drug release. The patent study explores new dimensions on MSNs synthesis by claiming new cost-effective templates and silica source, a more safe environment for synthesis, reducing synthesis steps, duration of reaction, effective loading of low solubility drugs by magnetized nanocarriers, pathogen-specific release and development of novel photoluminescent rechargeable MSNs under mild conditions. It’s a challenging task for researchers to successfully translate their prototypes to industries and make it feasible for commercialization. We can further work on excellent targeting concepts and architecture of MSNs for the increased opportunity in cancer theranostics.

Keywords: Breast cancer, mesoporous silica nanoparticles, targeting ligands, stimuli-responsive, templates, toxicity, patent survey.

« Previous Next »
Graphical Abstract

[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Sarnath D, Khanna A. Current status of cancer burden: Global and Indian scenario. Biomed Res J 2014; 1: 1-5.
[http://dx.doi.org/10.4103/2349-3666.240996]
[3]
Dikshit R, Gupta PC, Ramasundarahettige C, et al. Million eath study collaborators. Cancer mortality in india: a nationally representative survey. Lancet 2012; 379(9828): 1807-16.
[http://dx.doi.org/10.1016/S0140-6736(12)60358-4] [PMID: 22460346]
[4]
American Cancer Society. Cancer Facts & Figures 2019.
[5]
Aziz ZABA, Ahmad A, Mohd-Setapar SH, et al. Recent Advances in Drug Delivery of Polymeric Nano-Micelles. Curr Drug Metab 2017; 18(1): 16-29.
[http://dx.doi.org/10.2174/1389200217666160921143616] [PMID: 27654898]
[6]
Wani AW, Baig U, Shreaz S, et al. Recent advances in iron complexes as potential anticancer agents. New J Chem 2016; 40: 1063-90.
[http://dx.doi.org/10.1039/C5NJ01449B]
[7]
Rahmani S, Budimir J, Sejalon M, et al. Large pore mesoporous silica and organosilica nanoparticles for pepstatin a delivery in breast cancer cells. Molecules 2019; 24(2): 332.
[http://dx.doi.org/10.3390/molecules24020332] [PMID: 30658511]
[8]
Sábio RM, Meneguin AB, Ribeiro TC, Silva RR, Chorilli M. New insights towards mesoporous silica nanoparticles as a technological platform for chemotherapeutic drugs delivery. Int J Pharm 2019; 564: 379-409.
[http://dx.doi.org/10.1016/j.ijpharm.2019.04.067] [PMID: 31028801]
[9]
Kresge CT, Leonowicz ME, Roth WJ, Vartuli JC, Beck JS. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 1992; 359: 710-71.
[http://dx.doi.org/10.1038/359710a0]
[10]
Tsai CH, Vivero-Escoto JL, Slowing II, Fang IJ, Trewyn BG, Lin VS. Surfactant-assisted controlled release of hydrophobic drugs using anionic surfactant templated mesoporous silica nanoparticles. Biomaterials 2011; 32(26): 6234-44.
[http://dx.doi.org/10.1016/j.biomaterials.2011.04.077] [PMID: 21684000]
[11]
Wang B, Zhang K, Wang J, Zhao R, Zhang Q, Kong X. Poly(amidoamine)-modified mesoporous silica nanoparticles as a mucoadhesive drug delivery system for potential bladder cancer therapy. Colloids Surf B Biointerfaces 2020.189110832
[http://dx.doi.org/10.1016/j.colsurfb.2020.110832] [PMID: 32070865]
[12]
Bagshaw AS, Pinnavaia TJ. Mesoporous alumina molecular sieves. Angm Chem. Ed EngI 1996; 35: 1-10.
[13]
Huo Q, Feng J, Ferdi S, Stucky GD. Preparation of Hard Mesoporous Silica Spheres. Chem Mater 1997; 9: 14-7.
[http://dx.doi.org/10.1021/cm960464p]
[14]
Zhao D, Feng J, Huo Q, et al. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. Science 1998; 279(5350): 548-52.
[http://dx.doi.org/10.1126/science.279.5350.548] [PMID: 9438845]
[15]
Che S, Garcia-Bennett AE, Liu X, et al. Synthesis of large-pore Ia3d mesoporous silica and its tubelike carbon replica. Angew Chem Int Ed Engl 2003; 42(33): 3930-4.
[http://dx.doi.org/10.1002/anie.200351752] [PMID: 12949872]
[16]
Lin YS, Tsai CP, Huang HY, et al. Well-ordered mesoporous silica nanoparticles as cell markers. Chem Mater 2005; 17: 4570-3.
[http://dx.doi.org/10.1021/cm051014c]
[17]
Bharali DJ, Klejbor I, Stachowiak EK, et al. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci USA 2005; 102(32): 11539-44.
[http://dx.doi.org/10.1073/pnas.0504926102] [PMID: 16051701]
[18]
Celer EB, Jaroniec JAM. Temperature-programmed microwave-assisted synthesis of SBA-15 ordered mesoporous silica. J Am Chem Soc 2006; 128(44): 14408-14.
[http://dx.doi.org/10.1021/ja065345h]
[19]
Han L, Sakamoto Y, Terasaki O, Li Y, Che S. Synthesis of carboxylic group functionalized mesoporous silicas (CFMSs) with various structures. J Mater Chem 2006; 17: 1216-21.
[http://dx.doi.org/10.1039/b615209k]
[20]
Cho EB, Volkov DO, Sokolov I. Ultrabright fluorescent mesoporous silica nanoparticles. Small 2010; 6(20): 2314-9.
[http://dx.doi.org/10.1002/smll.201001337] [PMID: 20859948]
[21]
Ma Y, Xing L, Zheng H, Che S. Anionic-cationic switchable amphoteric monodisperse mesoporous silica nanoparticles. Langmuir 2011; 27(2): 517-20.
[http://dx.doi.org/10.1021/la103979c] [PMID: 21166445]
[22]
Lin G, Anfeng Z, Keke H, Chengyi D, Shuguang Z, Min L, et al. One-pot hydrothermal synthesis of mesoporous silica nanoparticles using formaldehyde as growth suppressant. Microporous Mesoporous Mater 2012; 152: 9-15.
[http://dx.doi.org/10.1016/j.micromeso.2011.11.047]
[23]
Hu X, Wang Y, Peng B. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release. Chem Asian J 2014; 9(1): 319-27.
[http://dx.doi.org/10.1002/asia.201301105] [PMID: 24115568]
[24]
Lovingood DD, Owens JR, Seeber M, Kornev KG, Luzinov I. Preparation of silica nanoparticles through microwave-assisted acid-catalysis. J Vis Exp 2013; 82(82)e51022
[http://dx.doi.org/10.3791/51022] [PMID: 24379052]
[25]
Zhang Q, Wang X, Li PZ, et al. Biocompatible, Uniform, and Redispersible Mesoporous Silica Nanoparticles for Cancer-Targeted Drug Delivery In vivo. Adv Funct Mater 2014; 24: 2450-61.
[http://dx.doi.org/10.1002/adfm.201302988]
[26]
Fang Y, Zheng G, Yang J, et al. Z, Jian.; Zhang, F.; Zhao, D.A. Dual-Pore Mesoporous Carbon@Silica Composite Core–Shell Nanospheres for Multidrug Delivery. Chem Int Ed 2014; 53: 1-6.
[http://dx.doi.org/10.1002/anie.201402002]
[27]
Khosravian P, Shafiee Ardestani M, Khoobi M, et al. Mesoporous silica nanoparticles functionalized with folic acid/methionine for active targeted delivery of docetaxel. OncoTargets Ther 2016; 9: 7315-30.
[http://dx.doi.org/10.2147/OTT.S113815] [PMID: 27980423]
[28]
Hakeem A, Zahid F, Zhan G, et al. Polyaspartic acid-anchored mesoporous silica nanoparticles for pH-responsive doxorubicin release. Int J Nanomedicine 2018; 13: 1029-40.
[http://dx.doi.org/10.2147/IJN.S146955] [PMID: 29497295]
[29]
Guha A, Biswas N, Bhattacharjee K, Das P, Kuotsu K. In vitro evaluation of pH responsive doxazosin loaded mesoporous silica nanoparticles: a smart approach in drug delivery. Curr Drug Deliv 2016; 13(4): 574-81.
[http://dx.doi.org/10.2174/1567201812666150722123704.] [PMID: 26201344.]
[30]
Kang KK, Oh HS, Kim DY, Shim G, Lee CS. Synthesis of silica nanoparticles using biomimetic mineralization with polyallylamine hydrochloride. J Colloid Interface Sci 2017; 507: 145-53.
[http://dx.doi.org/10.1016/j.jcis.2017.07.115] [PMID: 28783518]
[31]
Agrawal G, Schürings M, Zhu X, Pichg A. Microgel/SiO2 hybrid colloids prepared using a water soluble silica precursor. Polymer (Guildf) 2012; 53: 1189-97.
[http://dx.doi.org/10.1016/j.polymer.2012.01.051]
[32]
Yu Q, Wang P, Hu S, Hui J, Zhuang J, Wang X. Hydrothermal synthesis of hollow silica spheres under acidic conditions. Langmuir 2011; 27(11): 7185-91.
[http://dx.doi.org/10.1021/la200719g] [PMID: 21553827]
[33]
Zhao P, Liu MC, Lin HC, Sun XY, Li YY, Yan SQ. Synthesis and drug delivery applications for mesoporous silica nanoparticles. J Mod Biotechnol 2017; 1: 1-8.
[34]
Kamarudin NHN, Jalil AA, Triwahyono S, Timmiati SN. Microwave-assisted synthesis of mesoporous silica nanoparticles as a drug delivery vehicle. Malays J Anal Sci 2016; 20: 1382-9.
[http://dx.doi.org/10.17576/mjas-2016-2006-17]
[35]
Li M, Zhang C, Yang XL, Xu HB. Controllable synthesis of hollow mesoporous silica nanoparticles templated by kinetic self-assembly using a gemini surfactant. RSC Advances 2013; 3: 163-04.
[http://dx.doi.org/10.1039/c3ra22805c]
[36]
Ismail AR, Vejayakumaran P. Synthesis of silica nanoparticles by sol-gel: size-dependent properties, surface modification, and applications in silica-polymer nanocomposites-a review. J Nanomater 2012; 132424: 1-15.
[37]
Samadi M. Vahid. Synthesis of mesoporous silica nanoparticles by means of a hydrogel. Int Nano Lett 2013; 3: 39.
[http://dx.doi.org/10.1186/2228-5326-3-39]
[38]
Zheng Q, Lin T, Wu H, et al. Mussel-inspired polydopamine coated mesoporous silica nanoparticles as pH-sensitive nanocarriers for controlled release. Int J Pharm 2014; 463(1): 22-6.
[http://dx.doi.org/10.1016/j.ijpharm.2013.12.045] [PMID: 24393764]
[39]
Bahrami Z, Badiei A, Atyabi F, Darabi HR, Mehravi B. Piperazine and its carboxylic acid derivatives-functionalized mesoporous silica as nanocarriers for gemcitabine: adsorption and release study. Mater Sci Eng C 2015; 49: 66-74.
[http://dx.doi.org/10.1016/j.msec.2014.12.069] [PMID: 25686928]
[40]
Sarkar A, Ghosh S, Chowdhury S, et al. Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells. BBA. Gen Subjects 2016; 860: 2065-75.
[http://dx.doi.org/10.1016/j.bbagen.2016.07.001]
[41]
Shen J, He Q, Gao Y, Shi J, Li Y. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism. Nanoscale 2011; 3(10): 4314-22.
[http://dx.doi.org/10.1039/c1nr10580a] [PMID: 21892492]
[42]
Skorupska E, Jeziorna A, Paluch P, Potrzebowski MJ. Ibuprofen in mesopores of Mobil Crystalline Material 41 (MCM-41): a deeper understanding. Mol Pharm 2014; 11(5): 1512-9.
[http://dx.doi.org/10.1021/mp400670f] [PMID: 24694363]
[43]
Mellaerts R, Jammaer JA, Van Speybroeck M, et al. Physical state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case study with itraconazole and ibuprofen. Langmuir 2008; 24(16): 8651-9.
[http://dx.doi.org/10.1021/la801161g] [PMID: 18630936]
[44]
Zhang Z, Quan G, Wu Q, et al. Loading amorphous Asarone in mesoporous silica SBA-15 through supercritical carbon dioxide technology to enhance dissolution and bioavailability. Eur J Pharm Biopharm 2015; 92: 28-31.
[http://dx.doi.org/10.1016/j.ejpb.2015.02.018] [PMID: 25720818]
[45]
Guan J, Han J, Zhang D, et al. Increased dissolution rate and oral bioavailability of hydrophobic drug glyburide tablets produced using supercritical CO2 silica dispersion technology. Eur J Pharm Biopharm 2014; 86(3): 376-82.
[http://dx.doi.org/10.1016/j.ejpb.2013.10.008] [PMID: 24184803]
[46]
Gignone A, Manna L, Ronchetti S, et al. Incorporation of clotrimazole in ordered mesoporous silica by supercritical CO2. Microporous Mesoporous Mater 2014; 200: 291-6.
[http://dx.doi.org/10.1016/j.micromeso.2014.05.031]
[47]
Van Speybroeck M, Mellaerts R, Mols R, et al. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur J Pharm Sci 2010; 41(5): 623-30.
[http://dx.doi.org/10.1016/j.ejps.2010.09.002] [PMID: 20850527]
[48]
Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009; 8(7): 543-57.
[http://dx.doi.org/10.1038/nmat2442] [PMID: 19525947]
[49]
Xia T, Kovochich M, Liong M, et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 2009; 3(10): 3273-86.
[http://dx.doi.org/10.1021/nn900918w] [PMID: 19739605]
[50]
Morishige T, Yoshioka Y, Inakura H, et al. The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1beta production, ROS production and endosomal rupture. Biomaterials 2010; 31(26): 6833-42.
[http://dx.doi.org/10.1016/j.biomaterials.2010.05.036] [PMID: 20561679]
[51]
Nabeshi H, Yoshikawa T, Arimori A, et al. Effect of surface properties of silica nanoparticles on their cytotoxicity and cellular distribution in murine macrophages. Nanoscale Res Lett 2011; 6(1): 93.
[http://dx.doi.org/10.1186/1556-276X-6-93] [PMID: 21711578]
[52]
Shirshahi V, Shamsipour F, Zarnani AH, Verdi J, Saber R. Active targeting of HER2-positive breast cancer cells by Herceptin-functionalized organically modified silica nanoparticles. Cancer Nanotechnol 2013; 4(1-3): 27-37.
[http://dx.doi.org/10.1007/s12645-013-0035-6] [PMID: 26069499]
[53]
Ma B, He L, You Y, Mo J, Chen T. Controlled synthesis and size effects of multifunctional mesoporous silica nanosystem for precise cancer therapy. Drug Deliv 2018; 25(1): 293-306. [Patents]
[http://dx.doi.org/10.1080/10717544.2018.1425779] [PMID: 29334793]
[54]
Liong M, Jie L, Tamanoi F, Zink JI, Oaks S, Nel A. Mesoporous silicananoparticles for biomedical applications US Patent, 2010/0255103 A1, PCT/USO8/1347, 2010.
[55]
Hanif H, Nazir S, Mazhar K, Waseem M, Bano S, Rashid U. Targeted delivery of mesoporous silica nanoparticles loaded monastrol into cancer cells: an in vitro study. Appl Nanosci 2017; 7: 549-55.
[http://dx.doi.org/10.1007/s13204-017-0593-8]
[56]
Ferris DP, Lu J, Gothard C, et al. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small 2011; 7(13): 1816-26.
[http://dx.doi.org/10.1002/smll.201002300] [PMID: 21595023]
[57]
Guo X, Guo N, Zhao J, Cai Y. Active targeting co-delivery system based on hollow mesoporous silica nanoparticles for antitumor therapy in ovarian cancer stem-like cells. Oncol Rep 2017; 38(3): 1442-50.
[http://dx.doi.org/10.3892/or.2017.5829] [PMID: 28731164]
[58]
Zheng T, Wang A, Hu D, Wang Y. Tumor-targeting templated silica nanoparticles as a dual-drug delivery system for anti-angiogenic ovarian cancer therapy. Exp Ther Med 2017; 14(3): 2162-70.
[http://dx.doi.org/10.3892/etm.2017.4777] [PMID: 28962137]
[59]
Du X, Zhang T, Ma G, Gu X, Wang G, Li J. Glucose-responsive mesoporous silica nanoparticles to generation of hydrogen peroxide for synergistic cancer starvation and chemistry therapy. Int J Nanomedicine 2019; 14: 2233-51.
[http://dx.doi.org/10.2147/IJN.S195900] [PMID: 31118604]
[60]
Cheng J, Liu Q, Shuhendler AJ, Rauth AM, Wu XY. Optimizing the design and in vitro evaluation of bioreactive glucose oxidase-microspheres for enhanced cytotoxicity against multidrug resistant breast cancer cells. Colloids Surf B Biointerfaces 2015; 130: 164-72.
[http://dx.doi.org/10.1016/j.colsurfb.2015.04.002] [PMID: 25896537]
[61]
Badr G, Sayed D, Maximous D, Mohamed AO, Gul M. Increased susceptibility to apoptosis and growth arrest of human breast cancer cells treated by a snake venom-loaded silica nanoparticles. Cell Physiol Biochem 2014; 34(5): 1640-51.
[http://dx.doi.org/10.1159/000366366] [PMID: 25401286]
[62]
Rejeeth C, Salem A, Salemb A. Novel luminescent silica nanoparticles (LSN): p53 gene delivery system in breast cancer in vitro and in vivo. J Pharm Pharmacol 2016; 68(3): 305-15.
[http://dx.doi.org/10.1111/j.2042-7158.2012.01547.x] [PMID: 27085860]
[63]
Nhavene EPF, Andrade GF, Quintão JA, Faria A, Gomes DA, Sousa EMB. Biodegradable polymers grafted onto multifunctional mesoporous silica nanoparticles for gene delivery. Chem Eng 2018; 2: 24.
[http://dx.doi.org/10.3390/chemengineering2020024]
[64]
Fan J, Fang G, Wang X, Zeng F. Xiang.; Shuizhu, W. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles. Nanotechnology 2011; 22: 11.
[http://dx.doi.org/10.1088/0957-4484/22/45/455102]
[65]
Hanafi-Bojd MY, Moosavian Kalat SA, Taghdisi SM, Ansari L, Abnous K, Malaekeh-Nikouei B. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells. Drug Dev Ind Pharm 2018; 44(1): 13-8.
[http://dx.doi.org/10.1080/03639045.2017.1371734] [PMID: 28832225]
[66]
Park S, Park H, Jeong S, Yi BG, Park K, Key J. Hyaluronic acid-conjugated mesoporous silica nanoparticles loaded with dual anticancer agents for chemophotodynamic cancer therapy. Journal ofanomaterials 2019; 3481397: 1-11.
[http://dx.doi.org/10.1155/2019/3481397]
[67]
Ultimo A, Giménez C, Bartovsky P, et al. Targeting Innate Immunity with dsRNA-Conjugated Mesoporous Silica Nanoparticles Promotes Antitumor Effects on Breast Cancer Cells. Chemistry 2016; 22(5): 1582-6.
[http://dx.doi.org/10.1002/chem.201504629] [PMID: 26641630]
[68]
Liu CM, Chen GB, Chen HH, et al. Cancer cell membrane-cloaked mesoporous silica nanoparticles with a pH-sensitive gatekeeper for cancer treatment. Colloids Surf B Biointerfaces 2019; 175: 477-86.
[http://dx.doi.org/10.1016/j.colsurfb.2018.12.038] [PMID: 30572156]
[69]
Tzankov B, Voycheva C, Yordanov Y, et al. Development and in vitro safety evaluation of pramipexole-loaded hollow mesoporous silica (HMS) particles. Biotechnol Biotechnol Equip 2019; 33(1): 1204-15.
[http://dx.doi.org/10.1080/13102818.2019.1649094]
[70]
Croissant JG, Zhang D, Alsaiari S, et al. Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. J Control Release 2016; 229: 183-91.
[http://dx.doi.org/10.1016/j.jconrel.2016.03.030] [PMID: 27016140]
[71]
Chang D, Gao Y, Wang L, et al. Polydopamine-based surface modification of mesoporous silica nanoparticles as pH-sensitive drug delivery vehicles for cancer therapy. J Colloid Interface Sci 2016; 463: 279-87.
[http://dx.doi.org/10.1016/j.jcis.2015.11.001] [PMID: 26550786]
[72]
Tambe P, Kumar P, Paknikar KM, Gajbhiye V. Decapeptide functionalized targeted mesoporous silica nanoparticles with doxorubicin exhibit enhanced apoptotic effect in breast and prostate cancer cells. Int J Nanomedicine 2018; 13: 7669-80.
[http://dx.doi.org/10.2147/IJN.S184634] [PMID: 30538451]
[73]
Murugan B, Gandhi S, Sethuraman S, Krishnan UM. Chemosensitive mesoporous silica nanocarriers for photodynamic therapy against breast cancer. J Nanosci Nanotechnol 2017; 17: 8806-17.
[http://dx.doi.org/10.1166/jnn.2017.13890]
[74]
Guo W, Yang C, Cui L, Lin H, Qu F. An enzyme-responsive controlled release system of mesoporous silica coated with Konjac oligosaccharide. Langmuir 2014; 30(1): 243-9.
[http://dx.doi.org/10.1021/la403494q] [PMID: 24380643]
[75]
Mondragan L, Nfflria M, Ferragud V, Torre C, Agostini A. Enzyme-responsive intracellular-controlled release using silica mesoporous nanoparticles capped with e-poly-l-lysine. Chemistry 2014; 20: 1-12.
[http://dx.doi.org/10.1002/chem.201400148]
[76]
Zou Z, He X, He D, et al. Programmed packaging of mesoporous silica nanocarriers for matrix metalloprotease 2-triggered tumor targeting and release. Biomaterials 2015; 58: 35-45.
[http://dx.doi.org/10.1016/j.biomaterials.2015.04.034] [PMID: 25941780]
[77]
Chen X, Sun H, Hu J, Han X, Liu H, Hu Y. Transferrin gated mesoporous silica nanoparticles for redox-responsive and targeted drug delivery. Colloids Surf B Biointerfaces 2017; 152: 77-84.
[http://dx.doi.org/10.1016/j.colsurfb.2017.01.010] [PMID: 28088015]
[78]
Zhang L, Li Y, Jin Z, Yu JC, Chan KM. An NIR-triggered and thermally responsive drug delivery platform through DNA/copper sulfide gates. Nanoscale 2015; 7(29): 12614-24.
[http://dx.doi.org/10.1039/C5NR02767E] [PMID: 26147639]
[79]
Li N, Wang Z, Zhang Y, et al. Curcumin-loaded redox-responsive mesoporous silica nanoparticles for targeted breast cancer therapy. Artif Cells Nanomed Biotechnol 2018; 46(sup2): 921-35.
[http://dx.doi.org/10.1080/21691401.2018.1473412] [PMID: 29790797]
[80]
Tran AV, Shim K, Vo Thi TT, Kook JK, An SSA, Lee SW. Targeted and controlled drug delivery by multifunctional mesoporous silica nanoparticles with internal fluorescent conjugates and external polydopamine and graphene oxide layers. Acta Biomater 2018; 74: 397-413.
[http://dx.doi.org/10.1016/j.actbio.2018.05.022] [PMID: 29775731]
[81]
Lai J, Shah BP, Zhang Y, Yang L, Lee KB. Real-time monitoring of ATP-responsive drug release using mesoporous-silica-coated multicolor upconversion nanoparticles. ACS Nano 2015; 9(5): 5234-45.
[http://dx.doi.org/10.1021/acsnano.5b00641] [PMID: 25859611]
[82]
Kim IY. Toxicity of silica nanoparticles depends on size, dose, and cell type. Nanomedicine Nanotechnology. Biol Med (Aligarh) 2015; 11: 407-1416.
[83]
Slowing II, Wu CW, Vivero-Escoto JL, Lin VS. Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. Small 2009; 5(1): 57-62.
[http://dx.doi.org/10.1002/smll.200800926] [PMID: 19051185]
[84]
Yu T, Greish K, McGill LD, Ray A, Ghandehari H. Influence of geometry, porosity, and surface characteristics of silica nanoparticles on acute toxicity: their vasculature effect and tolerance threshold. ACS Nano 2012; 6(3): 2289-301.
[http://dx.doi.org/10.1021/nn2043803] [PMID: 22364198]
[85]
Lankoff A, Arabski M, Ciuk AW, et al. Effect of surface modification of silica nanoparticles on toxicity and cellular uptake by human peripheral blood lymphocytes in vitro. Nanotoxicology 2013; 7(3): 235-50.
[http://dx.doi.org/10.3109/17435390.2011.649796 ] [PMID: 22264124]
[86]
Zhang Q, Wang X. Biocompatible, uniform, and redispersiblemesoporous silica nanoparticles for cancer-targeted drug delivery in vivo. Adv Funct Mater 2014; 24: 2450-61.
[http://dx.doi.org/10.1002/adfm.201302988]
[87]
Lin YS, Haynes CL. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. J Am Chem Soc 2010; 132(13): 4834-42.
[http://dx.doi.org/10.1021/ja910846q] [PMID: 20230032]
[88]
Oh WK, Kim S, Choi M, et al. Cellular uptake, cytotoxicity, and innate immune response of silica-titania hollow nanoparticles based on size and surface functionality. ACS Nano 2010; 4(9): 5301-13.
[http://dx.doi.org/10.1021/nn100561e] [PMID: 20698555]
[89]
Yu T, Hubbard D, Ray A, Ghandehari H. In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics. J Control Release 2012; 163(1): 46-54.
[http://dx.doi.org/10.1016/j.jconrel.2012.05.046] [PMID: 22684119]
[90]
Chauhan S, Manivasagam G, Kumar P, Ambasta RK. Cellular toxicity of mesoporous silica nanoparticle in SHSY5Y and BMMNCS cell. Pharm Nanotechnol 2018; 6(4): 245-52.
[http://dx.doi.org/10.2174/2211738506666181031160108] [PMID: 30381088]
[91]
Hao N, Liu H, Li L, Chen D, Li L, Tang F. In vitro degradation behavior of silica nanoparticles under physiological conditions. J Nanosci Nanotechnol 2012; 12(8): 6346-54.
[http://dx.doi.org/10.1166/jnn.2012.6199] [PMID: 22962747]
[92]
Huang X, Young NP, Townley HE. Characterization and comparison of mesoporous silica particles for optimized drug delivery. Nanomater Nanotechnol 2014; 4: 2.
[http://dx.doi.org/10.5772/58290]
[93]
Wu P, He X, Wang K, et al. Imaging breast cancer cells and tissues using peptide-labeled fluorescent silica nanoparticles. J Nanosci Nanotechnol 2008; 8(5): 2483-7.
[http://dx.doi.org/10.1166/jnn.2008.18282] [PMID: 18572669]
[94]
Benezra M, Penate-Medina O, Zanzonico PB, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest 2011; 121(7): 2768-80.
[http://dx.doi.org/10.1172/JCI45600] [PMID: 21670497]
[95]
Yamaguchi H, Hayama K, Sasagawa I, et al. HER2-targeted multifunctional silica nanoparticles specifically enhance the radiosensitivity of HER2-overexpressing breast cancer cells. Int J Mol Sci 2018; 19(3): 908.
[http://dx.doi.org/10.3390/ijms19030908] [PMID: 29562708]
[96]
Freitas LB, Corgosinho LM, Faria JAQA, Santos VM, Resende JM, Leal AS. Multifunctional mesoporous silica nanoparticles for cancer-targeted, controlled drug delivery and imaging. Microporous Mesoporous Mater 2017; 242: 271-83.
[http://dx.doi.org/10.1016/j.micromeso.2017.01.036]
[97]
Uppal A, Jain B, Gupta PK, Das K. Photodynamic action of Rose Bengal silica nanoparticle complex on breast and oral cancer cell lines. Photochem Photobiol 2011; 87(5): 1146-51.
[http://dx.doi.org/10.1111/j.1751-1097.2011.00967.x] [PMID: 21749397]
[98]
Jeffrey Z, Bastian R, Marcus L, Clemens DL, Clemens BYL. Pathogen-specific cargo delivery and diagnostic platform based on mesoporous silica nanoparticles U.S. Patent, 2019321486 A1, 2019.
[99]
Bierbach U, Zheng YE, Singh R. Compositions and associated methods of mesoporous nanoparticles comprising platinum-acridine molecules. US Patent, 2019/290685 A1/ WO 2018081553 A1, 2019.
[100]
Gang H, Zhanjun L. Homogeneous persistent luminescence nanocrystals and methods of preparation and application thereof.US Patent, 2019/292452 (A1), 2019.
[101]
Yang Y, Wang A, Junbai L. Preparation method of mesoporous silica nanoparticles C.N. Patent CN104628007 A, 2015.
[102]
Fanzhu L, Guowei W, Rongrong Z, et al. Carry the preparation method of resveratrol-loaded and amido-modified mesoporous silica nanoparticles C.N. Patent, CN104367552 A, 2017.
[103]
Bradbury MS, Wiesner U, Medina OP, Burns A, Lewis JS, Larson SM. Multimodal silica-based nanoparticles U.S. Patent 9,999,694 B2, 2018.
[104]
Chen F, Ma K, Zhang L, et al. Target-or-clear zirconium-89 labeled silica nanoparticles for enhanced cancer-directed uptake in melanoma: a comparison of radiolabeling strategies. Chem Mater 2017; 29(19): 8269-81.
[http://dx.doi.org/10.1021/acs.chemmater.7b02567] [PMID: 29123332]

Rights & Permissions Print Cite
Article Metrics
38
2
© 2024 Bentham Science Publishers | Privacy Policy